Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Weight-loss jabs for children ‘are effective and help prevent mealtime battles’

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.

Evening Standard

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

Fortune

Novo Nordisk Blames Compounders As It Cuts 2025 Forecast. But Shares Jump.

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of GLP-1 medicines.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

The Guardian - UK

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Euronews

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

MarketBeat

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

CVS customers can get weight-loss drug Wegovy at a discount for cash

But you'll have to pay cash.

Fortune

Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results.

Euronews

Ozempic is growing in popularity — it’s also sending people to the ER

An analysis of emergency visits related to the active ingredient in drugs like Ozempic and Wegovy has exposed a surprising effect

The Independent UK

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

MarketBeat

Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions

Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of the drugs that have not been approved by the FDA

The Independent UK

You might soon be able to get Wegovy from an online shop — here is where you need to visit

The move comes as Danish drugmaker Novo Nordisk has acted to slash the popular weight loss drug’s price

The Independent UK

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Today: Dow Jones Pops After Trade Deal News; A Genetic Testing Stock Breaks Out (Live Coverage)

The Dow Jones led the major indexes Tuesday afternoon as the Nasdaq lagged. Coca-Cola and Pfizer stocks jumped on the stock market today.

Investors Business Daily

Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy

Hims stock launched Tuesday after the company inked a deal to offer Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform.

Cycling Weekly

'I was calorie counting – I couldn't eat one blueberry over': How one British rider overcame years of underfueling and turned pro

A diabetes diagnosis didn’t stop Hamish Armitt from reaching his potential – but an eating disorder almost did

Fortune

CFO of Europe’s most valuable company hopes trade war is a ‘wake-up call’ for the continent

SAP’s finance chief, Dominik Asam, hopes tariffs are a “wake-up call” that can kick-start Europe into building more tech giants.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Medical Daily

FDA Alert: Fake Ozempic Found in US Drug Supply Chain

The FDA has issued a warning about counterfeit Ozempic injections circulating in the U.S., urging consumers to check labels and report adverse effects

International Business Times UK

WeightWatchers Filing For Bankruptcy: Iconic Program Founded In 1963 Loses Clients To Ozempic And More

Founded in 1963, WeightWatchers faces bankruptcy with £1.25 billion ($1.6 billion) in debt, losing clients to drugs like Ozempic. Can the iconic programme survive?

The Guardian - UK

EU drug companies warn of exodus to US as Trump threatens import tariffs

Von der Leyen urged to take ‘rapid and radical action’ as president says tariffs on pharmaceuticals coming ‘shortly’

Fortune

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Investors Business Daily

Humana, UnitedHealth, Other Insurers Jump On Medicare Advantage Payment Hike

The Trump administration says it will raise Medicare Advantage payments sharply, good news for Humana, UnitedHealth and other health insurers.

Investors Business Daily

Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

17 stories

Sima Sistani

13 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.